Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model,
This article was originally published in The Pink Sheet Daily
Executive Summary
From offices in North Carolina and Hangzhou, the start-up will in-license compounds to sell in China while developing its own candidates.
You may also be interested in...
Soon To Start Antibiotic Trial In China, MicuRx Gets $25M For U.S. Testing
A six-year-old start-up founded by Vicuron veterans has strong preclinical and Phase I data for a novel antibiotic targeting Gram-positive infections. Its cross-border approach will soon support two mid-stage trials.
Alnylam Finds Partner For Liver Cancer Program In China’s Ascletis
U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.
Ascletis Strategy Begins To Reach Fruition In Deal With Alnylam For HCC Candidate
U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.